BACKGROUND INFORMATION ON THE PROCEDURE

1. Submission of the dossier

The applicant Aventis Pharma Deutschland GmbH submitted on 5 June 2003 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Apidra, in accordance with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Dr. Ian Hudson Co-Rapporteur: Dr. Steffen Thirstrup

Licensing status:

The product was not licensed in any country at the time of submission of the application.

2. Steps taken for the assessment of the product

- The procedure started on 23 June 2003
- The Rapporteur's first assessment report was circulated to all CHMP Members on 16 September 2003. The Co-Rapporteur's first assessment report was circulated to all CHMP Members on 10 September 2003.
- During the meeting on 22 October 2003 the CHMP agreed on the consolidated list of questions to be sent to the company. The final consolidated list of questions was sent to the company on 23 October 2003.
- The company submitted the responses to the consolidated list of questions on 22 January 2004.
- The Rapporteurs circulated the response assessment report on the company's responses to the list of questions to all CHMP Members on 25 February 2004.
- During the CHMP meeting on 24 March 2004, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or oral explanation by the applicant.
- During the meeting on 01-03 June 2004, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Apidra on 3 June 2004.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 27 September 2004.